RedHill Biopharma Ltd. (RDHL)
After hours:
| Previous close | 0.4507 |
| Open | 0.4674 |
| Bid | 0.4468 x 200 |
| Ask | 0.4529 x 200 |
| Day's range | 0.4498 - 0.4674 |
| 52-week range | 0.2570 - 3.2800 |
| Volume | |
| Avg. volume | 551,070 |
| Market cap | 14.356M |
| Beta (5Y monthly) | 3.46 |
| PE ratio (TTM) | 0.11 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
- PR Newswire
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.
- PR Newswire
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 p
